Alfred I. duPont Hospital for Children, P. O. Box 269, Wilmington, DE 19899, USA.
Pediatr Radiol. 2012 Jan;42(1):76-81. doi: 10.1007/s00247-011-2198-9. Epub 2011 Aug 30.
In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures.
To test the hypothesis that when fractures occur after cyclic pamidronate, they will be at the proximal or distal end of a pamidronate band.
Retrospective review of our CP patient database revealed 53 children who had received one or more complete courses of pamidronate therapy (five cycles over 12 months). Medical records were screened to identify children who had sustained a fracture or fractures after completing treatment.
Of 53 patients treated with pamidronate, only 14 sustained fractures after treatment. Radiographs were available for 11 patients, showing 19 fractures. Sixty-three percent of these fractures were located at a junction with pamidronate bands but not within the bands.
We propose stress risers as the mechanism for fractures that have occurred where bone mineral density abruptly changes as a result of cyclic administration of pamidronate. We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser.
在既往有骨折史的非卧床脑瘫(CP)人群中,应用帕米膦酸盐预防再次骨折并不总是有效。
检验以下假说,即在周期性应用帕米膦酸盐后发生骨折时,骨折将位于帕米膦酸盐带的近端或远端。
回顾性分析我们的 CP 患者数据库,发现有 53 例儿童接受了一个或多个完整疗程的帕米膦酸盐治疗(12 个月内 5 个周期)。筛选病历以确定在完成治疗后发生骨折或骨折的儿童。
在接受帕米膦酸盐治疗的 53 例患者中,只有 14 例在治疗后发生骨折。11 例患者的 X 线片显示 19 处骨折,其中 63%的骨折位于与帕米膦酸盐带交界处,但不在带内。
我们提出,骨矿物质密度因周期性应用帕米膦酸盐而突然变化是导致骨折的应力集中点的机制。我们展示了一个理论示例,说明了如何通过改变给药方式来降低这种比值,从而降低形成应力集中点的机会。